Capricor Therapeutics (CAPR) is poised for FDA approval of its Duchenne muscular dystrophy therapy, offering significant potential upside. With strong financial backing and positive analyst projections, CAPR presents attractive trading opportunities despite market skepticism.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing